scispace - formally typeset
B

Beant S. Gill

Researcher at University of Pittsburgh

Publications -  41
Citations -  1156

Beant S. Gill is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Radiation therapy & Brachytherapy. The author has an hindex of 15, co-authored 41 publications receiving 937 citations. Previous affiliations of Beant S. Gill include George Washington University & University of California, San Diego.

Papers
More filters
Journal ArticleDOI

National Cancer Data Base Analysis of Radiation Therapy Consolidation Modality for Cervical Cancer: The Impact of New Technological Advancements

TL;DR: Consolidation brachytherapy is a critical treatment component for locally advanced cervical cancer; however, there has been declining utilization of brachyTherapy, and increased use of IMRT and SBRT boost coupled with increased mortality risk should raise concerns about utilizing these approaches over brachyotherapy.
Journal ArticleDOI

Results of a Single Institution Experience with Dose-Escalated Chemoradiation for Locally Advanced Unresectable Non-Small Cell Lung Cancer.

TL;DR: The outcomes of a program of dose-escalated chemoradiotherapy for unresectable stage IIIA and IIIB NSCLC patients were consistent with other studies and showed no benefit to radiation doses above 66 Gy and maintaining low esophageal V60 and lung V5 were associated with lower morbidity and mortality.
Journal ArticleDOI

MRI-Guided High–Dose-Rate Intracavitary Brachytherapy for Treatment of Cervical Cancer: The University of Pittsburgh Experience

TL;DR: This study constitutes one of the largest reported series of MRI-guided brachytherapy in North America, demonstrating excellent local control with acceptable morbidity and may be warranted when feasible for adenocarcinomas to offset the risk of local failure.
Journal ArticleDOI

Anaplastic thyroid cancer: Prognostic factors, patterns of care, and overall survival.

TL;DR: Anaplastic thyroid cancer (ATC) represents a rare, aggressive malignancy and factors predictive for overall survival (OS) and treatment modality utilization are analyzed.
Journal ArticleDOI

Treatment Selection and Survival Outcomes in Early-Stage Diffuse Large B-Cell Lymphoma: Do We Still Need Consolidative Radiotherapy?

TL;DR: Use of consolidative RT after multiagent chemotherapy in DLBCL is decreasing in the modern era, and abandonment of combined-modality therapy in favor of chemotherapy alone negatively affects patient survival.